pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$CNTACentessa Pharmaceuticals plc

$CNTA40.500.00%
Altrincham, Cheshire, GBupdated 3mo ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
Phase 2: 2
2Phase 2
Phase 2
ORX-142
Sleep Disorders
Phase 2
cleminorexton
Idiopathic Hypersomnia (IH)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Centessa Pharmaceuticals plc jobs →

News

  • Lilly’s early-stage M&A quest finds $1.5B deal for Calytrix’s blood cancer work
    Eli Lilly's business development team has inked 14 buyouts this year so far, with Calytrix Bio tucking into the pharma’s oncology pipeline.
    biospace · 20h ago
  • Lilly secures another myelofibrosis option via $1.5B deal for JPM-founded Calytrix
    Eli Lilly has added another myelofibrosis prospect to its pipeline courtesy of a $1.5 billion deal for Massachusetts biotech Calytrix Bio.
    fiercebiotech · 1d ago
  • Eli Lilly scraps phase 2 Alzheimer's program after drug falls short of expectations
    Eli Lilly has dropped its phase 2 Alzheimer's disease program for mevidalen, marking another setback for the experimental drug as the Big Pharma expands its neuroscience pipeline through multibilli…
    fiercebiotech · 19d ago
  • M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy
    After a frantic second quarter, M&A steadied with just under $30 billion across 22 total transactions, according to a BioSpace analysis.
    biospace · 1mo ago
  • Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
    InnoCare Pharma is the latest addition to Eli Lilly’s dealmaking spree, which includes some of the biggest acquisitions this year: up to $7 billion for Kelonia Therapeutics in April and up to $7.8…
    biospace · 1mo ago
  • Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
    After former Legend Biotech CEO Ying Huang, Ph.D., left the company suddenly in July, Legend has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its nex…
    fiercebiotech · 2mo ago
  • Deal-hungry Lilly strikes up to $2.9B immuno play for Merida
    With the acquisition of Merida Biosciences, Eli Lilly is gaining a precision degradation platform for therapies that selectively target and destroy pathologic antibodies for allergic and autoimmune…
    biospace · 2mo ago
  • Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
    Eli Lilly has struck a deal to acquire Merida Biosciences for up to $2.875 billion, establishing a beachhead in efforts to treat disease through the selective degradation of pathogenic autoantibodies.
    fiercebiotech · 2mo ago
  • ‘A neuroscience revolution’: The GLP-like race to keep us awake and make billions doing it
    As the hype around the vast medical potential of GLP-1 drugs continues unabated, another peptide is starting to make its own mark.
    fiercebiotech · 2mo ago
  • Takeda leads wave of orexin drugs with potential to upend narcolepsy market
    The FDA’s August approval of Takeda’s Orzeyful for treating the full set of narcolepsy symptoms initiated a new era in the sleep market.
    biospace · 3mo ago
view all news mentions →
identifiers
ticker
$CNTA
SEC CIK
0001847903
country
GB
source
sec_tickers
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 52m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?